

Supplementary Table 1: Patients characteristics

Variable	Relapse			p-value ²
	Overall N = 48 ¹	No relapse N = 34 ¹	Relapse N = 14 ¹	
Age (years)	60 (56, 66)	60 (55, 68)	61 (56, 64)	0.98
Sex				0.41
Female	25 (52%)	19 (56%)	6 (43%)	
Male	23 (48%)	15 (44%)	8 (57%)	
MMR status				0.14
dMMR	11 (23%)	10 (29%)	1 (7.1%)	
pMMR	37 (77%)	24 (71%)	13 (93%)	
pN classification				0.79
pN1	26 (54%)	18 (53%)	8 (57%)	
pN2	22 (46%)	16 (47%)	6 (43%)	
pT classification				0.73
pT1	1 (2.1%)	1 (2.9%)	0 (0%)	
pT2	1 (2.1%)	1 (2.9%)	0 (0%)	
pT3	36 (75%)	26 (76%)	10 (71%)	
pT4	10 (21%)	6 (18%)	4 (29%)	
Stage 3 risk				0.94
High Risk (pT4 and/or N2)	27 (56%)	19 (56%)	8 (57%)	
Low Risk (pT1-3 and N1)	21 (44%)	15 (44%)	6 (43%)	
Bowel obstruction/ perforation				>0.99
No	31 (65%)	22 (65%)	9 (64%)	
Yes	17 (35%)	12 (35%)	5 (36%)	
Tumor Localization				0.27
Distal	21 (44%)	13 (38%)	8 (57%)	
Proximal	25 (52%)	20 (59%)	5 (36%)	
NA	2 (4.2%)	1 (2.9%)	1 (7.1%)	
Treatment				0.65
FOLFOX	23 (48%)	17 (50%)	6 (43%)	
FOLFOX + cetuximab	25 (52%)	17 (50%)	8 (57%)	

¹Median (IQR) or Frequency (%)

²Wilcoxon rank sum exact test; Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test